A UBE2O-AMPKα2 Axis that Promotes Tumor Initiation and Progression Offers Opportunities for Therapy.

[1]  W. Rathmell,et al.  AMPK Is Essential to Balance Glycolysis and Mitochondrial Metabolism to Control T-ALL Cell Stress and Survival. , 2016, Cell metabolism.

[2]  A. Turnbull,et al.  Multi-Scale Genomic, Transcriptomic and Proteomic Analysis of Colorectal Cancer Cell Lines to Identify Novel Biomarkers , 2015, PloS one.

[3]  R. Chapple,et al.  AMPK Protects Leukemia-Initiating Cells in Myeloid Leukemias from Metabolic Stress in the Bone Marrow. , 2015, Cell stem cell.

[4]  James Y. Dai,et al.  Copy number alterations detected by whole-exome and whole-genome sequencing of esophageal adenocarcinoma , 2015, Human Genomics.

[5]  M. White,et al.  Degradation of AMPK by a Cancer-Specific Ubiquitin Ligase , 2015, Cell.

[6]  J. Machiels,et al.  Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer , 2014, Breast Cancer Research.

[7]  Jessica K. Gagnon,et al.  Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic sequestration mediated by the atypical ubiquitin ligase UBE2O. , 2014, Molecular cell.

[8]  Takla Griss,et al.  Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α , 2014, Proceedings of the National Academy of Sciences.

[9]  Tao Zhou,et al.  mUbiSiDa: A Comprehensive Database for Protein Ubiquitination Sites in Mammals , 2014, PloS one.

[10]  G. Lenz,et al.  PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma , 2013, Proceedings of the National Academy of Sciences.

[11]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[12]  D. Hardie,et al.  LKB1 and AMPK and the cancer-metabolism link - ten years after , 2013, BMC Biology.

[13]  A. Bauer,et al.  Fine‐tuning BMP7 signalling in adipogenesis by UBE2O/E2‐230K‐mediated monoubiquitination of SMAD6 , 2013, The EMBO journal.

[14]  Zhijian J. Chen,et al.  Regulation of WASH-Dependent Actin Polymerization and Protein Trafficking by Ubiquitination , 2013, Cell.

[15]  P. Dijke,et al.  UBE2O negatively regulates TRAF6-mediated NF-κB activation by inhibiting TRAF6 polyubiquitination , 2013, Cell Research.

[16]  Takla Griss,et al.  AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. , 2013, Cell metabolism.

[17]  S. Kim,et al.  E3 Ubiquitin Ligase, WWP1, Interacts with AMPKα2 and Down-regulates Its Expression in Skeletal Muscle C2C12 Cells* , 2013, The Journal of Biological Chemistry.

[18]  Chunaram Choudhary,et al.  Proteomic Analyses Reveal Divergent Ubiquitylation Site Patterns in Murine Tissues* , 2012, Molecular & Cellular Proteomics.

[19]  Navdeep S. Chandel,et al.  AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress , 2012, Nature.

[20]  B. Viollet,et al.  Loss of AMP-Activated Protein Kinase-α2 Impairs the Insulin-Sensitizing Effect of Calorie Restriction in Skeletal Muscle , 2012, Diabetes.

[21]  D. Sabatini,et al.  mTOR Signaling in Growth Control and Disease , 2012, Cell.

[22]  D. Hardie,et al.  AMPK: a nutrient and energy sensor that maintains energy homeostasis , 2012, Nature Reviews Molecular Cell Biology.

[23]  Jae Yong Cho,et al.  AMPKα modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer. , 2012, Cancer research.

[24]  D. Gilliland,et al.  Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms , 2011, Blood cancer journal.

[25]  Vladimir Valera Romero,et al.  The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. , 2011, Cancer cell.

[26]  V. Vacic,et al.  Identification, analysis, and prediction of protein ubiquitination sites , 2010, Proteins.

[27]  Philip R Quinlan,et al.  Histological evaluation of AMPK signalling in primary breast cancer , 2009, BMC Cancer.

[28]  R. Shaw,et al.  The LKB1–AMPK pathway: metabolism and growth control in tumour suppression , 2009, Nature Reviews Cancer.

[29]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[30]  Jiawei Wu,et al.  Downregulation of AMP‐activated protein kinase by Cidea‐mediated ubiquitination and degradation in brown adipose tissue , 2008, The EMBO journal.

[31]  B. Turk,et al.  AMPK phosphorylation of raptor mediates a metabolic checkpoint. , 2008, Molecular cell.

[32]  Seiichi Mori,et al.  An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. , 2008, Cancer cell.

[33]  P. Hogg,et al.  Arsenical-based cancer drugs. , 2007, Cancer treatment reviews.

[34]  D. Hardie,et al.  Regulation of the energy sensor AMP-activated protein kinase by antigen receptor and Ca2+ in T lymphocytes , 2006, The Journal of experimental medicine.

[35]  C. Plass,et al.  DNA copy number gains in head and neck squamous cell carcinoma , 2006, Oncogene.

[36]  W. Gerald,et al.  Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy , 2005, Cancer.

[37]  P. Pandolfi,et al.  Impaired Fas response and autoimmunity in Pten+/- mice. , 1999, Science.

[38]  C. Cordon-Cardo,et al.  Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[39]  A. Prescott,et al.  AMP-activated protein kinase: greater AMP dependence, and preferential nuclear localization, of complexes containing the alpha2 isoform. , 1998, The Biochemical journal.

[40]  D. Hardie,et al.  The α1 and α2 isoforms of the AMP‐activated protein kinase have similar activities in rat liver but exhibit differences in substrate specificity in vitro , 1996 .

[41]  C. Pickart,et al.  Mechanism of ubiquitin conjugating enzyme E2-230K: catalysis involving a thiol relay? , 1996, Biochemistry.

[42]  B. Kemp,et al.  Mammalian AMP-activated Protein Kinase Subfamily (*) , 1996, The Journal of Biological Chemistry.

[43]  R. Matusik,et al.  Prostate cancer in a transgenic mouse. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[44]  D. Hardie,et al.  Role of the AMP-activated protein kinase in the cellular stress response , 1994, Current Biology.

[45]  R. Cardiff,et al.  Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.

[46]  C. Pickart,et al.  A novel, arsenite-sensitive E2 of the ubiquitin pathway: purification and properties. , 1989, Biochemistry.

[47]  R. Palmiter,et al.  The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice , 1985, Nature.

[48]  Jiang Yin,et al.  Metformin reverses multidrug resistance and epithelial–mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells , 2013, Molecular and Cellular Biochemistry.

[49]  Hollis G. Potter,et al.  Author Manuscript , 2013 .

[50]  J. Scott,et al.  The alpha1 and alpha2 isoforms of the AMP-activated protein kinase have similar activities in rat liver but exhibit differences in substrate specificity in vitro. , 1996, FEBS letters.